Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

ad low functional scores (overall condition score of 3.4 points on the Modified Cincinnati Knee Rating System). Patients were young (mean age of 37 years) and had moderate to large lesions (mean lesion size of 4.3 cm2) on the femoral chondyles (Lateral Femoral Chondyle, Medial Femoral Chondyle and Trochlea) and most patients had undergone at least one previous treatment for their cartilage injury. At their early follow-up, 75 percent of all patients experienced significant improvement in their knee function (mean improvement of 4.3 in overall condition). Of those patients, 87 percent sustained improvement at the later follow-up time point.

"Long-term durability of Carticel had not been evaluated in the United States and there was a critical need to determine if Carticel patients experienced sustained improvement," said Leanna M. Caron, vice president and general manager of Genzyme Biosurgery, the division that manufactures and commercializes Carticel. "This study demonstrates both the durability and value of Carticel and leads the field to conclude that a vast majority of this patient population maintained improvement years following their initial procedure."

Also at the AAOS meeting, a separate study conducted at the Brigham and Women's Hospital in Boston, Mass., Dr. Tom Minas reported the findings of a study that compared the results of ACI following a marrow stimulation technique versus no significant treatment (including simple debridement) performed on the same cartilage defect. The results indicate that marrow stimulation techniques may compromise the successful outcome of future ACI. Investigators collected data from 329 consecutive patients treated with Carticel for large and multiple defects (4.8 cm2 per lesion and 8.7 cm2 per patient) and had at least two years follow-up. They concluded that patients who had a previous marrow stimulation technique and were subsequently treated with ACI were three times more likely to fail than patients who ha
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  Holographic Optical Technologies of ... of holographic medical imaging, is entering the world of ... Launching on April 20 th , 2015, the campaign ... The 8-inch and 22-inch displays will allow consumers to ... first time. In addition to the two displays, the ...
(Date:3/27/2015)... March 27, 2015   Cypher Genomics, Inc., ... new data showing that, compared to a panel ... provided highly equivalent interpretations of whether certain genetic ... so in a fraction of the time. Cypher,s ... more comprehensive genetic analysis in non-invasive prenatal testing ...
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... Male breast cancer occasionally is misdiagnosed as gynaecomastia, which affects ... course of a lifetime, thereby causing the diseae to be ... "It is perhaps ironic,that tumours in men are easier to ... being discovered at a later stage in men than in ...
... Americans diagnosed with lung cancer each year. Because there are ... in their later stages, making them difficult to treat. A ... treatment. ,By going after that protein, the drug stops the ... of patients //taking the drug actually had their tumors shrink ...
... pressure medications are less likely to suffer dementia or ... new study in this month’s Archives of Internal Medicine. ... ranking as the eighth leading cause of death and ... prior incidence of stroke put people// at especially high ...
... music training and the popular herb Ginkgo biloba have benefits for ... in Chinese medicine for 5,000 years and has become a best ... past half decade. ,Researchers gave a series of tests on ... years of music lessons before age 12, and 30 who did ...
... adopted the Framework Convention on Tobacco Control (FCTC) aimed ... 2003. The Convention requires countries to impose restrictions on ... clean indoor air controls and strengthen legislation to clamp ... to save billions of lives and protect people’s health ...
... elderly people over age 85 have Alzheimer’s disease. Now, ... cause some postmenopausal women to develop dementia, which is ... ,Researchers from Wake Forest University studied more than 4,500 ... Health Initiative. The WHI came to an early end ...
Cached Medicine News:Health News:Breast Cancer in Men Often Underestimated and Under-treated 2Health News:Longer Lung Cancer Survival 2Health News:Music training and Ginkgo biloba benefit memory 2Health News:World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking, 2
... and probe system used together to quantify ... based system is a sandwich nucleic acid ... for RNA detection and quantification, by amplifying ... technology. Branched DNA allows immediate quantification of ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
...
For the qualitative detection of Infectious mononucleosis IgM heterophile antibodies in human whole blood, serum and plasma specimens....
Medicine Products: